{
  "abstract": "Alzheimer’s disease (AD) is a progressive and irreversible neurodegenerative disorder, the treatment of which remains a major clinical challenge. In recent years, significant progress has been made in the immunotherapy of AD. Notably, monoclonal antibodies targeting amyloid-β (Aβ) have already been applied in clinical practice. However, as macromolecular therapeutics, antibodies face substantial challenges in crossing the blood-brain barrier (BBB) efficiently. Systemic administration typically requires high dosages to achieve the therapeutic level of brain exposure, which may trigger adverse events such as amyloid-related imaging abnormalities (ARIA) and thus restrict their widespread clinical application. To resolve this problem, various engineering strategies for modifying anti-Aβ antibodies have been developed. This review summarizes four major modification categories: BBB-penetrating bispecific antibodies (BsAbs), glycosylation engineering, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR)-based cell therapies (including CAR-macrophages, CAR-T cells, and CAR-astrocytes). We provide an in-depth discussion of their delivery efficiency, targeting capability, and safety, aiming to lay a foundation for developing safer and more effective next-generation anti-Aβ antibody therapeutic strategies.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Neurology, Affiliated Hospital of Zunyi Medical University",
    "School of Medicine, Yale University",
    "Guizhou Provincial Key Laboratory of Innovation and Manufacturing for Pharmaceuticals, School of Pharmacy, Zunyi Medical University"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 5,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Shuang Li"
    },
    {
      "affs": [
        1
      ],
      "name": "Jiwei Gu"
    },
    {
      "affs": [
        0
      ],
      "name": "Zucai Xu"
    },
    {
      "affs": [
        2
      ],
      "name": "Chunyang He"
    },
    {
      "affs": [
        0
      ],
      "name": "Changyin Yu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/2yr45132fmxxf.bib",
  "cited_by": 0,
  "doi": "10.1186/s12916-026-05088-0",
  "fulltext_url": "https://doi.org/10.1186/s12916-026-05088-0",
  "id": "2yr45132fmxxf",
  "issns": [
    "1741-7015"
  ],
  "landing_url": "https://doi.org/10.1186/s12916-026-05088-0",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "R"
    ],
    [
      "openalex",
      "2737|Alzheimer's disease research and treatments"
    ]
  ],
  "openalex": "W7171640657",
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-07-01",
  "publisher": "BMC",
  "ris": "https://research.draconitic.com/paper/2yr45132fmxxf.ris",
  "sources": [
    {
      "first_seen": "2026-11-01T14:21:22Z",
      "native_id": "00c1de1e53c8437cbadcc25e8b614c53",
      "source": "doaj",
      "url": "https://doi.org/10.1186/s12916-026-05088-0"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2737|Alzheimer's disease research and treatments",
      "subfield": "physiology"
    }
  ],
  "title": "Advances in modified anti-Aβ antibodies for the treatment of Alzheimer’s disease",
  "title_text": "Advances in modified anti-Aβ antibodies for the treatment of Alzheimer’s disease",
  "type": "peer-reviewed",
  "updated_at": "2026-11-03T14:20:49Z",
  "url": "https://research.draconitic.com/paper/2yr45132fmxxf",
  "venue": "BMC Medicine",
  "versions": []
}